(Q53560049)

15 May 2018

title

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. (English)

1 reference

15 May 2018

multicenter clinical trial

main subject

1 reference

Grassegger A

1

1 reference

15 May 2018

Schuler G

2

1 reference

15 May 2018

Hessenberger G

3

1 reference

15 May 2018

Walder-Hantich B

4

1 reference

15 May 2018

Jabkowski J

5

1 reference

15 May 2018

MacHeiner W

6

1 reference

15 May 2018

Salmhofer W

7

1 reference

15 May 2018

Zahel B

8

1 reference

15 May 2018

Pinter G

9

1 reference

15 May 2018

Herold M

10

1 reference

15 May 2018

Klein G

11

1 reference

15 May 2018

Fritsch PO

12

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 October 1998

1 reference

15 May 2018

British Journal of Dermatology

published in

1 reference

15 May 2018

volume

139

1 reference

15 May 2018

page(s)

639-648

1 reference

15 May 2018

issue

4

1 reference

15 May 2018

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Treatment of systemic sclerosis with gamma-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Recombinant interferon-gamma in the treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Th1 and Th2 in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

Recombinant interferon-gamma (rIFN-gamma) in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1998.02460.X

10.1046/J.1365-2133.1998.02460.X

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

9892907

1 reference

15 May 2018